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Abstract
Endothelial dysfunction and increased arterial stiffness occur early in the pathogenesis of the metabolic syndrome and they are both
powerful independent predictors of cardiovascular risk. A high-fibre diet has been correlated with lower BMI and a lower incidence of
hyperlipidaemia, CVD, hypertension and diabetes. The present randomised, parallel-design study compared the effects of fibre intake
from a healthy diet v. fibre supplement diets on blood pressure (BP) and vascular function over 12 weeks. Overweight and obese
adults were randomised to one of three groups: control (with placebo), fibre supplement (FIB) or healthy eating group with placebo
(HLT). Systolic blood pressure (SBP) was lower in the FIB group compared with the control group at week 6, but not at week 12. However,
SBP was lower in the HLT group compared with control group at week 12. At week 6, the FIB group presented lower diastolic blood
pressure and augmentation index compared with the control group, but this result did not persist to the end of the study. The present
study did not show any improvements in BP or vascular function in overweight and obese individuals with psyllium fibre supplementation
over 12 weeks of intervention. However, a healthy diet provided the greatest improvements in BP in overweight and obese subjects.
Further research with hypertensive individuals is necessary to elucidate whether increased fibre consumption in the form of psyllium
supplementation may provide a safe and acceptable means to reduce BP, vascular function and the risk of developing CVD.
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Obesity is one of today’s most blatantly visible public health
problems, with an escalating global epidemic of overweight
and obesity taking over many parts of the world(1). Even in
many low-income countries, obesity is now rapidly increasing,
and often coexists in the same population with chronic under-
nutrition(2). Obesity significantly increases the risk of develop-
ing the metabolic syndrome, which carries with it the risk of
developing CVD and type 2 diabetes mellitus. The metabolic
syndrome consists of a combination of different abnormal-
ities(3), such as abdominal obesity, atherogenic dyslipidaemia,
insulin resistance, glucose intolerance, impaired endothelial
function, elevated blood pressure (BP) and inflammation(4).
Endothelial dysfunction and hypertension are associated
with increased cardiovascular (CVD) morbidity and mortality
and have been implicated in the development of atherosclero-
sis(5). A small reduction in BP of 2–5 mmHg results in reduc-
tions in total mortality and mortality as a result of stroke and
CVD(6). It has been proposed that diet may play an important
role in lowering BP and improving endothelial function(7–9).
Epidemiological studies(10,11) and clinical trials(12,13) have
shown that the intake of dietary fibre either in the form of
food or supplements(14) may be inversely correlated with BP
levels and might be able to decrease the risk of hypertension
development(15). Accordingly, an increase in dietary fibres
has been recommended by the WHO as a safe and practical
approach to CVD risk reduction in the hypertensive
population(16).
In an 8-week parallel-design study, treated hypertensive
patients were randomised to one of four groups, consuming
a low-protein (12·5 % energy), low-fibre (15 g/d) diet alone
or having supplements of soya protein (25 % energy), psyllium
(12 g fibre/d) or both protein and fibre(17). Results of this study
suggest that a diet containing fibre-rich grain, fruit and vege-
tables significantly decreases the need for anti-hypertension
medication and improves BP control in individuals with
hypertension(17).
Clinical trials on dietary fibre supplementation have
shown a wide variation in BP responses. In trials with concen-
trated fibre supplements(13,18,19), reductions in BP were larger
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than those found in trials with fibre-rich foods. Furthermore,
a meta-analysis on published randomised trials indicates that
increased dietary fibre consumption (from 7 to 13·3 g/d), from
mixed supplements pills, guava fruit or psyllium(13,17,20,21),
may provide a safe and acceptable means to reduce BP in
patients with hypertension(18) compared with those consum-
ing ,7 g/d. The study by Eliasson et al.(13) showed that
dietary fibre tablets containing a mixture of beet, barley and
citrus in a ratio of 60:30:10 (7 g/d) significantly reduced dias-
tolic blood pressure (DBP) in mildly hypertensive patients
(from 18 to 70 years old) compared with a control group
taking placebo (1 g fibre (starch)/d) tablets. These changes
were independent of changes in body weight(13). In the
study by Burke et al.(17), hypertensive patients were random-
ised to one of four groups in an 8-week factorial study of
parallel design in which they either (1) followed a low-
protein, low-fibre diet, (2) had supplements of soya protein
to increase protein intake to 25 % energy, (3) had psyllium
supplementation to provide an additional 12 g soluble fibre/d
or (4) had both protein and fibre. Results showed that the
combination of dietary protein and soluble fibre supplements
lowered BP additively (group 4) in hypertensive individ-
uals(17). In another study(21), seventy-two hypertensive
patients consuming a soluble diet containing 0·5–1·0 kg
of guava daily (13·3 g fibre/d) for 4 weeks had a decreased
systolic blood pressure (SBP) and DBP compared with those
in the control group (consuming their usual diet). Another
study has shown a significant reduction in both SBP and
DBP in individuals (presenting with high BP) consuming a
diet supplemented with 8 g/d of water-soluble fibre from
oat bran compared with those consuming a low-fibre diet
(1·3 g/d)(22).
In animal models, soluble fibre supplementation has been
suggested to improve the endothelial function and BP(23).
A diet supplemented with 3·5% plantago ovata husks (psyllium)
for 25 weeks has been shown to reduce SBP in obese diabetic
Zucker rats(23) as well as in spontaneously hypertensive
rats supplemented a 3 and 10 % diet for 30 d(24). In addition,
Goto Kakizaki type 2 diabetic rats presented reduced SBP
following long-term consumption of cereal dietary fibre (8 g
barley/100 g of diet) for 16 weeks(25). Both results suggest
that a high-fibre diet decreases BP in hypertensive, obese
and diabetic rats.
The differences in BP response might be explained by fibre
dose, type of fibre consumed or better compliance with diet-
ary supplements than with high-fibre diets(26). Intake of fibre
in the USA and many other Western countries is about 15 g
daily(27), which is only half the amount recommended by
the American Heart Association (25–30 g/d from foods)(28).
It is estimated that Australian adults consume 18–25 g dietary
fibre/d(29). This falls short of the Australian Government
recommendations of 25 g dietary fibre/d for adult women
and 30 g dietary fibre/d for men(30). Given this large
population segment with inadequate fibre intake, the demon-
stration of the beneficial effects of fibre on BP may have an
impact on public health policy.
Overweight and obesity is associated with an increased risk
of poor BP control(31) and hyperlipidaemia. The augmentation
index (AI) is an indicator of arterial stiffness and has been
shown to be higher in those with hypercholesterolaemia(32).
It has been suggested that the increase in arterial stiffening
may be associated with an increase in SBP and DBP(33–35).
Arterial stiffness is one of the major risk factors of CVD(36),
presenting an independent risk factor for this condition(36,37).
It is an age-related phenomenon(38,39) and its progression
is faster in patients with clusters of the metabolic syn-
drome(40–42), resulting in luminal enlargement with wall
thickening (remodelling) and a reduction in elastic properties
(stiffening) at the level of large elastic arteries, namely arterio-
sclerosis(43). Besides the metabolic syndrome(44), patients with
hypertension(45) or diabetes(46) exhibit increased carotid wall
thickness and stiffness and this ‘accelerated’ arterial ageing
is well confirmed to be a risk for CVD(47). It is currently
unknown whether fibre supplementation can improve
arterial stiffness.
Some mechanisms have been suggested to explain the
potential effect of dietary fibre intake on BP. Fibre seems to
decrease the lipid profile by increasing intestinal viscosity(48),
therefore reducing bile acid absorption and promoting choles-
terol catabolism(49). A high fibre intake is associated with a
decrease in total and LDL-cholesterol(50,51), thereby potentially
lowering the incidence of coronary disease(52). It has been
shown that serum cholesterol affects BP regulation(53) by
impairing endothelium-dependent dilation(54). Interestingly,
many hypertensive patients also appear to have increased
serum cholesterol levels(55). However, whether this is only a
statistical association or it also implies a pathophysiological
link is still under discussion(53). Hypercholesterolaemia is
associated with the loss of NO-induced vasodilation(56) and
the subsequent increase in BP(57). There is evidence that
cholesterol induces endothelial dysfunction even at normal
or high-to-normal ranges by reducing the bioavailability of
endothelium-derived NO(54,56). Higher cholesterol levels may
also be associated with more atherosclerotic vessels, not
only in the carotid circulation by the increase in intima-
media thickness, but also in other arteries(53). In addition,
water-soluble fibre seems to reduce insulin resistance in
both diabetic and healthy subjects(58,59), which is suggested
to be involved in the development of hypertension(60).
Hence, there is a possibility that fibre intake can also improve
BP and endothelial function in overweight individuals.
Currently, there is a lack of studies on the effects of increas-
ing dietary fibre intake on BP and arterial stiffness. A direct
comparison between a group taking fibre supplementation
alone and a group taking increased fibre by adopting a
healthy eating pattern needs to be undertaken to reveal
the effects from these different sources on chronic disease
risk factors in overweight and obese individuals.
Psyllium husk fibre is a viscous, mostly water-soluble fibre
and has been shown to be an effective supplement in adjunct
to dietary intervention to control blood cholesterol, TAG and
insulin levels in our previous studies(61,62). Therefore, the
aim of the present study was to investigate whether
12 weeks of additional dietary fibre intake in the form of
a healthy diet or dietary fibre supplement (psyllium) would
sustain improvements in vascular function and BP.



















Overweight and obese individuals with a BMI between 25 and
40 kg/m2 and aged between 18 and 65 years, presenting lipid
profile and glucose/insulin levels in any range were recruited
through local media (newspaper and television) from the
community of Perth, Australia. Of ninety-four respondents,
seventy-two were eligible to participate (thirty-seven men
and thirty-five women) and commenced the study. Potential
participants were screened by telephone and they attended
at Curtin University to assess their suitability for the study, at
which time the details of the study were explained. Exclusion
criteria included smoking, lipid-lowering medication, use of
steroids and other agents that may influence lipid metabolism,
use of warfarin, diabetes mellitus, hypo- and hyperthyroidism,
cardiovascular events within the last 6 months, psychological
unsuitability, major systemic diseases, gastrointestinal problems,
proteinuria, liver failure, renal failure, weight fluctuations
over the past 6 months and vegetarianism. The present
study was conducted according to the guidelines laid down
in the Declaration of Helsinki and all procedures involving
human subjects were approved by the Curtin University
Human Research Ethics Committee (approval no. HREC 157/
2004). All participants gave their written informed consent.
Study design
The present study was a randomised, single-blind, parallel
design over a 12-week period. The randomisation was done
based on sex and alphabetical sequences of the surnames.
The participants were allocated into two main groups of
males and females and their lists were sorted based on their
surnames alphabetically on a spreadsheet. The first name on
each list was allocated into group 1, the second name into
group 2 and the third name into group 3, and the same
sequence of 1, 2 and 3 was repeated for the rest of the
names, respectively, to allocate the participants into three
intervention groups randomly and to avoid any bias. The
study participants were randomised to one of three groups:
the control group (n 18), who consumed placebo with their
usual diet; the fibre supplement group (FIB, n 18), who con-
sumed a fibre supplement with their usual diet; a healthy
eating with placebo (HLT, n 18), who consumed placebo
with a healthy eating regimen. The fibre supplement consisted
of psyllium serving, which is a soluble fibre gel-forming muci-
lage from the Plantago ovata plant whose bioactive fraction
is a fibre composed of a highly branched arabinoxylan(63).
The participants were instructed to take 12 g of Metamucil
(Metamucil; P&G, Sydney, NSW, Australia) containing 7 g of
psyllium, three times a day, in a total extra fibre ingestion
of 21 g daily. A serving size of 12 g of Metamucil supplement
(two rounded teaspoons ¼ approximately 12 g) contains
approximately 7 g of dietary psyllium fibre, with the other
remaining 5 g being made up of citric acid, aspartame,
sunset yellow FCF CI 15985, maltodextrin, artificial and natural
orange flavour and Na. Psyllium has advantages over other
types of soluble fibre because it is less readily fermented and
therefore causes less flatulence and abdominal bloating(63).
It was used in the present study as it would be easily tolerated
and is readily marketed worldwide. The placebo consisted of
12 g of breadcrumbs with flavouring, which provided 1·5 g
of soluble fibre, presenting low energy and fibre content
and similarity in texture and appearance to the psyllium
supplement. The participants were asked to consume either
the placebo or fibre supplement mixed with 250 ml water,
5–10 min before breakfast, lunch and dinner.
The subjects attended a briefing session on how to
complete food records and comply with the study protocol.
Dietary intake over the course of the trial was monitored
through the completion of 3 d weighed food diaries at base-
line, 6 and 12 weeks. Ad libitum healthy eating plans, as
designed by a registered dietitian, were prescribed for the
HLT group for 12 weeks, which included healthy meals and
snacks based on the Dietary Guidelines for Australian Adults(64).
These study participants were asked to record their food and
drink intake for 3 d every 3 weeks to monitor the adherence
to the guidelines(64) and were given feedback and strategies
if necessary. These participants were closely monitored to
ensure their compliance with the dietary guidelines.
The participants in the control and FIB groups were asked
to maintain their usual dietary intake for the duration of
the study. To monitor compliance, all the participants were
provided with a measuring cup to measure either the fibre
supplement or the placebo, they were required to complete
a diary to record their supplement consumption and they
were asked to return the empty and non-empty containers
of the supplements at their 6- and 12-week visits.
Assessments
Subjects were asked to visit the Curtin University for measure-
ments, in a fasted state and wearing light clothing, on three
occasions, one for baseline measures, at 6 weeks and at
12 weeks. Body weight (UM-018 Digital Scales; Tanita,
Tokyo, Japan) was recorded in light clothing. Height was
measured to the nearest 0·1 cm, without shoes, using a stadi-
ometer (26SM 200 cm; SECA, Hamburg, Germany). Waist
circumference was measured in the standing position at the
narrowest area between the lateral lower rib and the iliac
crest. Hip measurement was taken at the largest circumference
of the lower abdomen. The waist and hip measurements were
taken three times at baseline, week 6 and week 12. The aver-
age at each time point was then reported. BP was measured
with an automated, calibrated sphygmomanometer (Dinamap;
Compact T, Critikon, Germany), with subjects in a supine
position after resting for at least 10 min. The measurements
were taken on the same arm three times at 1 min intervals.
These readings were then averaged.
Pulse-wave analysis for augmentation index
Pulse-wave analysis was used to assess arterial stiffness and
vascular function using the SphygmoCore (AtCor Medical,
Sydney, NSW, Australia). SphygmoCor is a non-invasive
device that enables aortic root pressure to be measured

















during a normal clinical consultation. All pulse-wave analysis
measurements were taken in a quiet, temperature-controlled
room (228C), after a period of at least 5 min of rest. Patients
fasted overnight and were asked to refrain from drinking
drinks containing caffeine. Only high-quality readings, defined
as an in-device quality index of 90 % (derived from an algor-
ithm including average pulse height, pulse height variation,
diastolic variation and the maximum rate of rise of the periph-
eral waveform) and acceptable curves by visual inspection by
the investigator, were included in the analysis.
Measurements were taken in the fasting state at baseline,
week 6 and week 12. For each assessment, at least three
measurements were taken and results were averaged. The
AI is negative in healthy young people, but with ageing
or increasing cardiovascular risk, arteries stiffen and the AI
becomes increasingly positive. The AI was calculated using
the following formula: AI (%) ¼ augmentation pressure/
(SBP 2 DBP) £ 100. The reference range provided by the
Sphygmocor software (AtCor Medical) was determined from
an analysis of 405 healthy individuals in a study by Wilkinson
et al.(65). Mean population AI at age 50 years was 18·43 (90 %
CI 20·17, 39·97) %. All measurements were performed by the
same operator. These measurements were taken three times
with a quality index of at least 90 % or over and the readings
were averaged.
Statistical analysis
Statistical analysis was undertaken using SPSS 11 for Windows
(SPSS, Inc., Chicago, IL, USA). Data are expressed as means
with their standard errors and assessed for normality to
ensure that the assumptions of the analysis are met. Data
were analysed using multivariate ANOVA with baseline
values considered as covariates. If significant between-group
effects were present, post hoc comparisons between the treat-
ment groups were made using the least significant difference
method. Statistical significance was considered at P,0·05.
A sample size of at least fifteen subjects per group will
provide sufficient power (0·90 %) to detect an estimated
within- and between-group effect size of 0·56 at a 5 % signifi-
cance level. Recruiting a total of seventy-two subjects (n 18)
will allow for 20 % dropouts.
The present clinical trial was registered with the Australian
New Zealand Clinical Trials Registry. The registration no. is




A total of seventy-two individuals were randomly assigned
to one of the three test groups: control, FIB or HLT. Of
these, fifteen participants withdrew from the study due to
unrelated illness, work commitments, poor compliance and
personal reasons. The remaining fifty-seven participants
(twenty-five males and thirty-two females) completed the
12-week study (control: n 15; FIB: n 16; HLT: n 12). Baseline
values of clinical and vascular characteristics in the three treat-
ment arms were not significantly different (Table 1). Although
there were some reports of minor bloating initially, all
subjects tolerated the supplements well with no adverse
effects reported.
Diet analysis
The self-reported food and drink intake at baseline, 6 and
12 weeks is shown in Table 2. There were no significant differ-
ences in total energy, carbohydrate, protein, total fat, saturated
fat, monounsaturated fat, polyunsaturated fat and fibre
between the three groups at baseline.
Fibre intake was higher (P,0·001) in the FIB group
by 20·5 g and in the HLT group by 11 g at week 12 when
compared with the control group. Fibre intake in the FIB
group was also higher (P,0·001) than the HLT group by
9·6 g at week 12.
Total fat intake was lower (P,0·001) in the HLT group by
6 % at week 6 and by 24 % at week 12 when compared with
the control group. When compared with the FIB group, total
fat intake was lower (P,0·001 and P¼0·020, respectively) in
the HLT group by 10 % at week 6 and lower (P,0·001) by
18 % at week 12. Saturated fat intake was increased
(P,0·05) in the control group at 12 weeks when compared
with baseline. The HLT group also showed an increase
(P,0·05) in saturated fat at 12 weeks when compared with
baseline. Saturated fat intake was reduced (P¼0·029) by
26 % in the HLT group when compared with the control
group at week 12. Polyunsaturated fat intake was also lower
(P¼0·018) in the HLT group by 23 % when compared with
the control group at week 12. Monounsaturated fat intake in
the HLT group was lower (P¼0·008) by 24 % at week 6 and
lower (P¼0·047) by 20 % at week 12 when compared with
the control group.
Effects of fibre on blood pressure
Resting BP was measured in the fasting state, at baseline, week
6 and week 12, and there were no significant differences in
SBP or DBP. Between-group analysis revealed that SBP was
Table 1. Clinical and vascular characteristics of subjects at baseline
(Mean values with their standard errors)*
Groups. . . Control FIB HLT
Characteristics Mean SEM Mean SEM Mean SEM
Age (years) 44·8 1·6 41·3 2·3 40·8 3·0
Weight (kg) 97·8 3·2 101·6 3·0 101·9 4·6
BMI (kg/m2) 33·7 1·0 34·0 0·9 36·1 1·5
WC (cm) 104·8 3·0 110·2 3·5 110·9 3·5
Waist:hip ratio 0·9 2·1 0·9 2·8 0·8 2·7
SBP (mmHg) 114·3 2·7 115·0 2·5 111·3 3·0
DBP (mmHg) 66·3 2·3 66·4 2·6 62·6 2·6
AI (%) 40·0 7·0 26·6 4·3 30·1 5·2
FIB, fibre supplement group; HLT, healthy eating with placebo; WC, waist circum-
ference; SBP, systolic blood pressure; DBP, diastolic blood pressure; AI,
augmentation index.
* Mean values were not significantly different between subject characteristics at
screening.

















lower in the FIB group by 7 % (P¼0·04) compared with
the control group at week 6. SBP was lower in the HLT
group by 9 % (P¼0·02) compared with the control group
at week 12 (Fig. 1(a)). There were no differences in SBP
between the other intervention groups at week 12 compared
with the control group.
Analysis between the groups at week 6 showed that DBP
was lower by 7 % (P¼0·04) and 3 % (P¼0·04) in the FIB and
HLT groups, respectively, compared with the control group.
When DBP results were analysed at week 12, there was no
difference between the groups (Fig. 1(b)).
Effects of fibre on vascular function
Central AI was measured in the fasting state, at baseline, week
6 and week 12, and there were no significant differences
within the groups at 6 or 12 weeks from baseline. Analysis
of data between the groups showed that the AI was lower
by 22 % in the FIB group compared with the control group
(P¼0·02) at week 6, but it was not different between the
groups at week 12 (Fig. 2).
Discussion
The aim of the present study was to investigate whether
12 weeks of consumption of a fibre supplement or a healthy
eating diet would induce improvements to BP and arterial
stiffness in overweight and obese individuals compared with
a standard diet. SBP was significantly lower in the FIB group
at week 6 compared with the control group. However, these
changes were temporary and the only significant difference
in SBP at week 12 was between the HLT and control
groups. DBP was lower in the FIB group compared with the
control group at week 6, but this did not last and there
were no significant differences in DBP between the groups
at the end of the study. Collectively, the present study
showed that fibre supplementation in the form of psyllium
had no effect on BP and endothelial function; however,
increased fibre intake in the form of a healthy diet was
beneficial to lowering BP.
Some mechanisms have been suggested to explain the
potential effect of dietary fibre intake on BP, since dietary
fibre presents numerous effects on the digestion and absorp-
tion of foods. The mechanism by which fibre lowers CVD
Table 2. Reported dietary intake data assessed by weighed food records†
(Mean values with their standard errors, n 57)
Baseline Week 6 Week 12
Mean SEM Mean SEM Mean SEM
Total EI
Control 8054·1 428·4 8325 629·2 8165·7a 509·2
FIB 8375·9 467·1 7817·4 359·6 7756·8a,b 369·2
HLT 8266·3 479·2 7807·6 422·7 7255·4a,b 325·4
Carbohydrate (%EI)
Control 43·8 2·4 43·8 2·4 44·5 2·2
FIB 45·9 2·0 45·5 1·5 46·3 2·1
HLT 45·8 1·7 47·1 1·7 49·9 2·1
Protein intake (%EI)
Control 18·3 1·3 18·2 1·2 18·2 1·0
FIB 17·7 1·1 18·5 1·0 19·3 1·1
HLT 17·4 1·1 19·3 1·1 21·8* 1·2
Fat intake (%EI)
Control 37·8 1·9 37·8a 2·1 37·1a 2·1
FIB 36·2 1·5 35·9a 0·9 34·3a 1·7
HLT 36·6 1·6 32·3*b 1·4 28·2*b 1·1
SFA intake (%EI)
Control 14·4 1·2 17·8 1·3 19·7*a 1·9
FIB 14·6 1·0 17·0 0·8 17·4a,b 1·1
HLT 12·4 0·8 16·1* 1·0 14·6*b 1·1
MUFA intake (%EI)
Control 14·2 0·8 13·7a 1·1 11·4*a 1·0
FIB 14·2 0·7 13·0a 0·8 11·3*a,b 0·7
HLT 14·5 0·6 10·4*b 1·0 9·0*b 0·6
PUFA intake (%EI)
Control 9·2 1·2 6·3* 0·6 6·0*a 0·5
FIB 7·5 0·7 5·9* 0·3 5·7*a,b 0·5
HLT 9·8 1·3 5·9* 0·6 4·6*b 0·4
Fibre intake (g)
Control 23·7 1·2 19·7*a 0·6 19·7*a 0·6
FIB 23·9 1·0 38·1*b 2·0 40·3*c 1·9
HLT 24·0 1·0 31·6c 1·2 30·7b 0·6
EI, energy intake; FIB, fibre supplement group; HLT, healthy eating with placebo.
a,b,c Mean values with unlike superscript letters were significantly different between the groups at 6 and 12 weeks (P,0·05).
* Mean values were significantly different from baseline (P,0·05).
† Nutritional data recorded in 3 d food diaries at baseline, week 6 and week 12.

















risk remains to be determined; however, studies have
suggested that fibre decreases the lipid profile by increasing
intestinal viscosity(48), therefore reducing bile acid absorption
and promoting cholesterol catabolism(49). In particular, a high
fibre intake is associated with a decrease in the serum concen-
trations of total and LDL-cholesterol(50,51) and, at the same
time, with a lower incidence of coronary disease(52). In addi-
tion, water-soluble fibre seems to reduce insulin resistance
and insulin plasma concentrations in both diabetic and healthy
subjects(58,59). Insulin resistance is implicated in the patho-
genic mechanism for the development of hypertension(60).
Although little is known about the potential mechanisms
by which dietary fibre may lower BP, there are a few studies
investigating the beneficial effects of dietary fibre intake on
BP. Studies with animals have suggested that a high-fibre
diet decreases BP in hypertensive, obese and diabetic rats(23,24).
In fact, prospective observational studies that have analysed
the relationship between dietary fibre intake and the risk of
developing hypertension have indicated that an increased
consumption of dietary fibre intake is inversely related to BP
and may contribute to prevent hypertension(17,18,31,66), in
both hypertensive or normotensive subjects.
In the present study, SBP and DBP were lower in the FIB
group compared with the control group at week 6. However,
this change appears to have been temporary as there were no
significant differences in SBP and DBP between any groups
at week 12. This discrepancy may have been due to lower
BP in the control group at week 12. This may be due to
day-to-day variability in BP(67) or to some other factors such
as psychological stress and mood which can affect BP
levels(68). However, the reason why this would occur in the
control group and not affect the other groups in the present
study is unknown. The other possibility for no difference in
BP between the groups after 12 weeks of study was that the
average BP of the groups was within the healthy range and
it is hard to highlight the BP differences in normotensive
participants, as dietary fibre usually makes small changes in
BP in these groups(66,69).
A good body of evidence supports the adoption of a diet
high in fruits, vegetables and fibre and low in fat, which
suggests that such a diet helps protect against CVD and dia-
betes(70). Thus, the psyllium supplement consumed in the
present study may not be as effective as the multiple sources
of fibre from consuming non-viscous fibres and pectin from
whole grain, fruit and vegetables. Furthermore, there is evi-
dence that soluble fibre improves mineral absorption in the
digestive system(71,72), which may have a favourable effect
on BP. In the Dietary Approaches to Stop Hypertension trial,
the effect of dietary patterns on BP was assessed. The fruits-
and-vegetables diet provided K, Mg and high amounts of
fibre, and resulted in BP reductions of 2·8/1·1 mmHg com-
pared with a typical US diet. Other studies have provided
support for an increased effect of soluble fibre on BP(14).
In addition, several other mechanisms for a potential effect
of dietary fibre intake on BP have been hypothesised. Dietary
fibre has numerous effects on the digestion and absorption of
foods and can change the glycaemic index of foods, thereby
altering insulin response. Insulin plays a role in BP regulation
and dietary fibre can modify the insulin and vascular endo-
thelial function(73). Insulin resistance and its concomitant
compensatory hyperinsulinaemia have been suggested as
major underlying pathogenetic mechanisms for the develop-
ment of hypertension(74). In this way, the effectiveness of both
(a) 


































Fig. 1. Blood pressure levels at baseline, week 6 and week 12 between
the three intervention groups (control (–X–) n 15, fibre supplement group
(FIB; –B–) n 16, healthy eating with placebo (HLT; –O–) n 12). (a) Systolic
blood pressure (SBP, mmHg) and (b) diastolic blood pressure (DBP, mmHg).
Values are means, with their standard errors represented by vertical bars.
* Mean values were significantly different between the FIB v. control groups
(P,0·05). † Mean values were significantly different between the HLT v.
control groups (P,0·05).














Fig. 2. Central augmentation index (AI; %) at baseline, week 6 and week 12
between the three intervention groups (control (–X–) n 15, fibre supplement
group (FIB; –B–) n 16, healthy eating with placebo (–O–) n 12). Values are
means, with their standard errors represented by vertical bars. * Mean values
were significantly different between the FIB v. control groups (P,0·05).

















soluble and insoluble fibres in reducing insulin resistance
and insulin levels in both diabetic and healthy persons(75,76)
would contribute to treating or preventing hypertension.
Our previous studies showed that simply adding psyllium
fibre supplementation to a normal diet was sufficient to
see improvements in total and LDL-cholesterol as well as
body weight, BMI and percentage of body fat compared
with the control group. However, there was no effect of
psyllium fibre supplementation on insulin levels, but fasting
insulin levels decreased at week 12 in the HLT group by
24 % (P¼0·03) compared with baseline(61). When compared
with the control group at week 12, insulin levels decreased
in the HLT group by 21 % (P¼0·001). Given that insulin
plays a regulatory role on BP, the lack of change in insulin
levels in the FIB group may partially explain why fibre sup-
plementation did not affect BP in the FIB group.
In subjects with the metabolic syndrome, the AI, an indi-
cator of arterial stiffness, was shown to be significantly
higher than in subjects with normal weight for the same age
and mean arterial pressure(77,78). Thus, this measurement is
one of the most appropriate for repeat determinations in clini-
cal studies. Studies have shown an inverse relationship
between healthy eating and arterial stiffness(79). Compared
with a low-fibre meal (12–16 % carbohydrate containing
0·5 g cereal fibre), a mix of high-carbohydrate, high-fibre
meal (69–76 % carbohydrate containing 19 g cereal fibre) has
been shown to improve flow-mediated dilation through
increasing NO release in subjects with the metabolic syn-
drome(80). However, the role of dietary fibre in preventing
and improving arterial stiffness in the short and long term
has yet to be fully elucidated. Endothelial function has an
important role in regulating BP and vascular resistance(81).
Consumption of psyllium husk has been shown to alter the
endothelial function and SBP in Zucker rats(23). The hypoten-
sive effect of psyllium was attributed, at least in part, to its abil-
ity to inhibit intestinal absorption of Na and improve the
endothelial function by improving hyperlipidaemia and
decreasing the inflammatory markers(24). The present data
analysis showed that the central AI did not change over 12
weeks of intervention from the baseline in any group. Data
analysis between the groups showed that the AI was lower
by 22 % in the FIB group compared with the control group
at week 6; however, this did not last and there were no signifi-
cant differences in the AI between the groups at the end of the
study. This suggests that the mechanism of reduction of BP
following dietary supplementation with psyllium is related to
specific alterations in endothelial function. The present study
is the first to investigate the effect of psyllium husk on arterial
stiffness in human subjects. There is some evidence from
animal studies which supports the beneficial effects of psy-
llium on endothelial function, such as diabetic rats fed daily
with psyllium husk that showed improvement on endothelial
function and, consequently, on SBP by altering the endo-
thelium response to acetylcholine and improving inflamma-
tory markers(23). Markers of the endothelial function such
as NO were not measured in the present study, but it may
be one of the mechanisms that altered BP temporarily in the
intervention groups.
The amount of fibre supplementation of 21 g psyllium/d, as
well as the duration of the study of 12 weeks, was considered
suitable to detect differences in BP. Our choices were based
on previous studies confirming this information. A meta-
analysis based on the evidence from twenty-five randomised,
controlled clinical trial, conducted in 1477 participants with
or without hypertension observed that a fibre intake of
7·2–18·9 g/d reduced significantly both SBP (22·3 mmHg)
and DBP (21·97 mmHg), respectively. Trials whose duration
was 8 weeks or more in length showed a significant decrease
in SBP and DBP (23·12 and 21·14 mmHg, respectively)
mainly in hypertensive subjects but also in normotensive
subjects(18). Therefore, the dose of fibre and the duration of
the study length used in the present study are well above
the range used in previous trials showing the beneficial effects
of fibre on BP.
The present study has some limitations. Hypertensive
subjects on various medications such as lipid lowering, hyper-
tension, etc. had responded to our newspaper article but were
then excluded given the confounding effects of these medi-
cations. Therefore, the average BP of the participants in the
present study was within the healthy range. This may be the
reason why no differences in BP was observed between
the groups after 12 weeks of study, as it is hard to highlight
the BP differences in normotensive participants. Dietary fibre
usually makes only small changes in BP in normotensive
groups(66,69).
The lack of significant differences in SBP and DBP between
the FIB and HLT groups at the end of the study may also be
due to lower BP in the control group at week 12, due to
day-to-day variability in BP(67) or due to some other factors
such as psychological stress and mood which can affect BP
levels(68). However, the reason why this would occur in the
control group and not affect the other groups in the present
study is unknown. Based on the variability in BP observed
in the present study, the trial had very low power to detect
clinically meaningful changes.
The lack of any improvement in arterial stiffness in the FIB
and HLT groups may be due to the normal BP of the individ-
uals and the short duration of the study. A meta-analysis of
studies about the effects of healthy eating and dietary fibre
on BP and endothelial function showed that these effects
are more prominent in hypertensive individuals compared
with normotensive individuals, and significant changes are
usually measurable after a few months of intervention(18).
Future studies with hypertensive subjects would clarify
whether these results persist or not.
In summary, the present study did not show any improve-
ments in BP or vascular function in overweight and obese
individuals with psyllium fibre supplementation, although a
healthy diet decreased SBP. There may be factors in a healthy
diet affecting BP, which may not be related to an increase
in fibre. Further studies are required in hypertensive over-
weight and obese patients to examine whether psyllium
fibre supplementation can have beneficial effects on vascular
health and BP.
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